Mild traumatic brain injury-induced hippocampal gene expressions: The identification of target cellular processes for drug development

Journal of Neuroscience Methods

Volumn 272, Issue , 2016, Pages 4-18

  Tweedie, David ^a   Rachmany, Lital ^b   Kim, Dong Seok ^a,c   Rubovitch, Vardit ^b   Lehrmann, Elin ^a   Zhang, Yongqing ^a   Becker, Kevin G ^a   Perez, Evelyn ^a   Pick, Chaim G ^b   Greig, Nigel H ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b TEL AVIV UNIVERSITY   (Israel)

^c Peptron Inc   (South Korea)

Author keywords

Dementia; Gene expression; Gene ontology; Inflammation; Mild traumatic brain injury (mTBI); Molecular pathway; Neurodegeneration; Neurological

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR GAMMA2; 4 AMINOBUTYRIC ACID RECEPTOR; BIOLOGICAL MARKER; CHEMOKINE RECEPTOR; CHOLECYSTOKININ; COMPLEMENTARY DNA; CRYPTOCHROME 2; CYTOKINE; DJ 1 PROTEIN; DOPAMINE; DOPAMINE RECEPTOR; GLUTAMATE RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN DERIVATIVE; KELCH LIKE ECH ASSOCIATED PROTEIN 1; LEUKOTRIENE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MATRIX METALLOPROTEINASE 17; NEUROTRANSMITTER RECEPTOR; NICOTINIC RECEPTOR; OMEGA CONOTOXIN MVIIA; PROTEIN MSH6; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); RETINOIC ACID INDUCIBLE PROTEIN I; SEPTIN; SODIUM CHANNEL NAV1.1; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1A1; TRANSCRIPTION FACTOR JUNB; X BOX BINDING PROTEIN 1;

AGING; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DEGENERATIVE DISEASE; DRUG DEVELOPMENT; GENE EXPRESSION; GENE ONTOLOGY; HIPPOCAMPAL TISSUE; HIPPOCAMPUS; MOUSE; NERVE CELL NECROSIS; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; SYNAPTIC TRANSMISSION; TRAUMATIC BRAIN INJURY; ANIMAL; BIOLOGY; BRAIN CONCUSSION; DISEASE MODEL; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; HEMISPHERIC DOMINANCE; INSTITUTE FOR CANCER RESEARCH MOUSE; METABOLISM; MICROARRAY ANALYSIS;

ANIMALS; BRAIN CONCUSSION; COMPUTATIONAL BIOLOGY; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; FUNCTIONAL LATERALITY; GENE EXPRESSION REGULATION; GENE ONTOLOGY; HIPPOCAMPUS; MICE, INBRED ICR; MICROARRAY ANALYSIS; TRANSCRIPTION, GENETIC;

EID: 84961227004     PISSN: 01650270     EISSN: 1872678X     Source Type: Journal    
DOI: 10.1016/j.jneumeth.2016.02.003     Document Type: Article

References (77)

1. Azevedo, F.A., Carvalho, L.R., Grinberg, L.T., Farfel, J.M., Ferretti, R.E., Leite, R.E., et al. Equal numbers of neuronal and nonneuronal cells make the human brain an isometrically scaled-up primate brain. J Comp Neurol 513 (2009), 532–541, 10.1002/cne.21974.
2. Ballesteros, J., Güemes, I., Ibarra, N., Quemada, J.I., The effectiveness of donepezil for cognitive rehabilitation after traumatic brain injury: a systematic review. J Head Trauma Rehabil 23 (2008), 171–180.
3. Baratz, R., Tweedie, D., Rubovitch, V., Luo, W., Yoon, J.S., Hoffer, B.J., et al. Tumor necrosis factor-α synthesis inhibitor, 3,6'-dithiothalidomide, reverses behavioral impairments induced by minimal traumatic brain injury in mice. J Neurochem 118 (2011), 1032–1042, 10.1111/j.1471-4159.2011.07377.x.
4. Baratz, R., Tweedie, D., Wang, J.Y., Rubovitch, V., Luo, W., Hoffer, B.J., et al. Transiently lowering tumor necrosis factor-α synthesis ameliorates neuronal cell loss and cognitive impairments induced by minimal traumatic brain injury in mice. J Neuroinflamm, 12, 2015, 45, 10.1186/s12974-015-0237-4.
5. Barkhoudarian, G., Hovda, D.A., Giza, C.C., The molecular pathophysiology of concussive brain injury. Clin Sports Med 30 (2011), 33–48.
6. Barnes, D.E., Kaup, A., Kirby, K.A., Byers, A.L., Diaz-Arrastia, R., Yaffe, K., Traumatic brain injury and risk of dementia in older veterans. Neurology 83 (2014), 312–319, 10.1212/WNL.0000000000000616.
7. Becker, R.E., Greig, N.H., Lost in translation: neuropsychiatric drug development. Sci Transl Med, 2, 2010, 61rv6.
8. Becker, R.E., Greig, N.H., Giacobini, E., Schneider, L.S., Ferrucci, L., A new roadmap for drug development for Alzheimer's disease. Nat Rev Drug Discov, 13, 2014, 156.
9. Becker, R.E., Seeman, M.V., Greig, N.H., Lahiri, D.K., What can triumphs and tribulations from drug research in Alzheimer's disease tell us about the development of psychotropic drugs in general. Lancet Psychiatry 2 (2015), 756–764.
10. Bergold, P.J., Treatment of traumatic brain injury with anti-inflammatory drugs. Exp Neurol, 2, 2015, 3, 10.1016/j.expneurol.2015.05.024 (pii: S0014-4886(15)00179-X).
11. Buttram, S.D., Wisniewski, S.R., Jackson, E.K., Adelson, P.D., Feldman, K., Bayir, H., et al. Multiplex assessment of cytokine and chemokine levels in cerebrospinal fluid following severe pediatric traumatic brain injury: effects of moderate hypothermia. J Neurotrauma 24 (2007), 1707–1717.
12. Choi, D.W., Mauluccigedde, M., Kriegstein, A.R., Glutamate neurotoxicity in cortical cell-culture. J Neurosci 7 (1987), 357–368.
13. ClinicalTrials.gov, ClinicalTrials.gov Identifier: NCT02240589. Memantine for neuroprotection and cognitive enhancement following traumatic brain injury. 2014 Initiated 2014 (https://clinicaltrials.gov/ct2/show/NCT02240589).
14. Cornelius, C., Crupi, R., Calabrese, V., Graziano, A., Milone, P., Pennisi, G., Traumatic brain injury: oxidative stress and neuroprotection. Antioxid Redox Signal 19 (2013), 836–853, 10.1089/ars.2012.4981.
15. Daneshvar, D.H., Goldstein, L.E., Kiernan, P.T., Stein, T.D., McKee, A.C., Post-traumatic neurodegeneration and chronic traumatic encephalopathy. Mol Cell Neurosci 66 (2015), 81–90, 10.1016/j.mcn.2015.03.007.
16. Ding, J., Ding, Z., Yuan, F., Guo, J., Chen, H., Gao, W., et al. Proteomics analysis after traumatic brain injury in rats: the search for potential biomarkers. Arq Neuropsiquiatr 73 (2015), 342–349, 10.1590/0004-282X20150006.
17. Eakin, K., Li, Y., Chiang, Y.H., Hoffer, B.J., Rosenheim, H., Greig, N.H., et al. Exendin-4 ameliorates traumatic brain injury-induced cognitive impairment in rats. PLoS ONE, 8, 2013, e82016.
18. Edut, S., Rubovitch, V., Schreiber, S., Pick, C.G., The intriguing effects of ecstasy (MDMA) on cognitive function in mice subjected to a minimal traumatic brain injury (mTBI). Psychopharmacology (Berl) 214 (2011), 877–889, 10.1007/s00213-010-2098-y.
19. Faul, M., Xu, L., Wald, M.M., Coronado, V.G., Traumatic brain injury in the United States: emergency department visits, hospitalizations and deaths 2002–2006. 2010, Centers for Disease Control and Prevention, National Center for Injury Prevention and Control, Atlanta, GA.
20. Fujiki, M., Kubo, T., Kamida, T., Sugita, K., Hikawa, T., Abe, T., et al. Neuroprotective and antiamnesic effect of donepezil, a nicotinic acetylcholine-receptor activator, on rats with concussive mild traumatic brain injury. J Clin Neurosci 15 (2008), 791–796, 10.1016/j.jocn.2007.07.002.
21. Gómez, P.A., de-la-Cruz, J., Lora, D., Jiménez-Roldán, L., Rodríguez-Boto, G., Sarabia, R., et al. Validation of a prognostic score for early mortality in severe head injury cases. J Neurosurg 121 (2014), 1314–1322, 10.3171/2014.7.JNS131874.
22. Greig, N.H., Tweedie, D., Rachmany, L., Li, Y., Rubovitch, V., Schreiber, S., et al. Incretin mimetics as pharmacologic tools to elucidate and as a new drug strategy to treat traumatic brain injury. Alzheimers Dement 10:1 Suppl (2014), S62–S75.
23. Greve, M.W., Zink, B.J., Pathophysiology of traumatic brain injury. Mt Sinai J Med 76 (2009), 97–104, 10.1002/msj.20104.
24. Gry, M., Rimini, R., Strömberg, S., Asplund, A., Pontén, F., Uhlén, M., et al. Correlations between RNA and protein expression profiles in 23 human cell lines. BMC Genomics, 10, 2009, 365, 10.1186/1471-2164-10-365.
25. Gupta, R., Sen, N., Traumatic brain injury: a risk factor for neurodegenerative diseases. Rev Neurosci, 2015, 10.1515/revneuro-2015-0017 pii:/j/revneuro.ahead-of-print/revneuro-2015-0017/revneuro-2015-0017.xml.
26. Gyorgy, A.B., Walker, J., Wingo, D., Eidelman, O., Pollard, H.B., Molnar, A., et al. Reverse phase protein microarray technology in traumatic brain injury. J Neurosci Methods 192 (2010), 96–101, 10.1016/j.jneumeth.2010.07.029.
27. Harris, N.G., Carmichael, S.T., Hovda, D.A., Sutton, R.L., Traumatic brain injury results in disparate regions of chondroitin sulfate proteoglycan expression that are temporally limited. J Neurosci Res 87 (2009), 2937–2950, 10.1002/jnr.22115.
28. Hölscher, C., Insulin, incretins and other growth factors as potential novel treatments for Alzheimer's and Parkinson's diseases. Biochem Soc Trans 42 (2014), 593–599.
29. Ikonomidou, C., Stefovska, V., Turski, L., Neuronal death enhanced by N-methyl-D-aspartate antagonists. Proc Natl Acad Sci USA 97 (2000), 12885–12890.
30. Israelsson, C., Bengtsson, H., Kylberg, A., Kullander, K., Lewén, A., Hillered, L., et al. Distinct cellular patterns of upregulated chemokine expression supporting a prominent inflammatory role in traumatic brain injury. J Neurotrauma 25 (2008), 959–974.
31. Israelsson, C., Wang, Y., Kylberg, A., Pick, C.G., Hoffer, B.J., Ebendal, T., Closed head injury in a mouse model results in molecular changes indicating inflammatory responses. J Neurotrauma 26 (2009), 1307–1314.
32. Kabadi, S.V., Stoica, B.A., Byrnes, K.R., Hanscom, M., Loane, D.J., Faden, A.I., Selective CDK inhibitor limits neuroinflammation and progressive neurodegeneration after brain trauma. J Cereb Blood Flow Metab 32 (2012), 137–149, 10.1038/jcbfm.2011.117.
33. Kim, S.Y., Volsky, D.J., PAGE: parametric analysis of gene set enrichment. BMC Bioinformatics, 6, 2005, 144, 10.1186/1471-2105-6-144.
34. Kondo, A., Shahpasand, K., Mannix, R., Qiu, J., Moncaster, J., Chen, C.H., et al. Antibody against early driver of neurodegeneration cis P-tau blocks brain injury and tauopathy. Nature 523 (2015), 431–436, 10.1038/nature14658.
35. Korley, F.K., Kelen, G.D., Jones, C.M., Diaz-Arrastia, R., Emergency department evaluation of traumatic brain injury in the United States, 2009–2010. J Head Trauma Rehabil, 2015, 10.1097/HTR.0000000000000187.
36. Kovesdi, E., Kamnaksh, A., Wingo, D., Ahmed, F., Grunberg, N.E., Long, J.B., et al. Acute minocycline treatment mitigates the symptoms of mild blast-induced traumatic brain injury. Front Neurol, 3, 2012, 111, 10.3389/fneur.2012.00111.
37. Lent, R., Azevedo, F.A., Andrade-Moraes, C.H., Pinto, A.V., How many neurons do you have? Some dogmas of quantitative neuroscience under revision. Eur J Neurosci 35 (2012), 1–9, 10.1111/j. 1460-9568.2011.07923.x.
38. Li, Y., Perry, T., Kindy, M.S., Harvey, B.K., Tweedie, D., Holloway, H.W., et al. GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc Natl Acad Sci USA 106 (2009), 1285–1290.
39. Li, Y., Duffy, K.B., Ottinger, M.A., Ray, B., Bailey, J.A., Holloway, H.W., et al. GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease. J Alzheimers Dis 19 (2010), 1205–1219, 10.3233/JAD-2010-1314.
40. Li, Y., Bader, M., Tamargo, I., Rubovitch, V., Tweedie, D., Pick, C.G., et al. Liraglutide is neurotrophic and neuroprotective in neuronal cultures and mitigates mild traumatic brain injury in mice. J Neurochem(May), 2015, 10.1111/jnc.13169.
41. Maas, A.I.R., Stocchetti, N., Bullock, R., Moderate and severe traumatic brain injury in adults. Lancet Neurol 7 (2008), 728–741.
42. Maier, T., Güell, M., Serrano, L., Correlation of mRNA and protein in complex biological samples. FEBS Lett 583 (2009), 3966–3973, 10.1016/j.febslet.2009.10.036.
43. Masanic, C.A., Bayley, M.T., VanReekum, R., Simard, M., Open-label study of donepezil in traumatic brain injury. Arch Phys Med Rehabil 82 (2001), 896–901.
44. Marklund, N., Hillered, L., Animal modeling of traumatic brain injury in preclinical drug development: where do we go from here. Br J Pharmacol 164 (2011), 1207–1229.
45. Milman, A., Rosenberg, A., Weizman, R., Pick, C.G., Mild traumatic brain injury induces persistent cognitive deficits and behavioral disturbances in mice. J Neurotrauma 9 (2005), 1003–1010.
46. Mukherjee, S., Katki, K., Arisi, G.M., Foresti, M.L., Shapiro, L.A., Early TBI-induced cytokine alterations are similarly detected by two distinct methods of multiplex assay. Front Mol Neurosci, 4, 2011, 21, 10.3389/fnmol.2011.00021.
47. Nakamura, K., Greenwood, A., Binder, L., Bigio, E.H., Denial, S., Nicholson, L., et al. Proline isomer-specific antibodies reveal the early pathogenic tau conformation in Alzheimer's disease. Cell 149 (2012), 232–244.
48. Naseem, M., Parvez, S., Role of melatonin in traumatic brain injury and spinal cord injury. ScientificWorldJournal, 2014, 586270, 10.1155/2014/586270.
49. Ozsüer, H., Görgülü, A., Kiriş, T., Cobanoğlu, S., The effects of memantine on lipid peroxidation following closed-head trauma in rats. Neurosurg Rev 28 (2005), 143–147.
50. Papa, M., De Luca, C., Petta, F., Alberghina, L., Cirillo, G., Astrocyte-neuron interplay in maladaptive plasticity. Neurosci Biobehav Rev 42 (2014), 35–54, 10.1016/j.neubiorev.2014.01.010.
51. Perry, T., Haughey, N.J., Mattson, M.P., Egan, J.M., Greig, N.H., Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4. J Pharmacol Exp Ther 302 (2002), 881–888.
52. Perry, T., Lahiri, D.K., Sambamurti, K., Chen, D., Mattson, M.P., Egan, J.M., et al. Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron. J Neurosci Res 72 (2003), 603–612.
53. Rachmany, L., Tweedie, D., Li, Y., Rubovitch, V., Holloway, H.W., Miller, J., et al. Exendin-4 induced glucagon-like peptide-1 receptor activation reverses behavioral impairments of mild traumatic brain injury in mice. Age (Dordr) 35 (2013), 1621–1636, 10.1007/s11357-012-9464-0.
54. Rachmany, L., Tweedie, D., Rubovitch, V., Yu, Q.S., Li, Y., Wang, J.Y., et al. Cognitive impairments accompanying rodent mild traumatic brain injury involve p53-dependent neuronal cell death and are ameliorated by the tetrahydrobenzothiazole PFT-α. PLoS ONE, 8, 2013, e79837.
55. Rao, V.L., Dogan, A., Todd, K.G., Bowen, K.K., Dempsey, R.J., Neuroprotection by memantine, a non-competitive NMDA receptor antagonist after traumatic brain injury in rats. Brain Res 911 (2001), 96–100.
56. Salcedo, I., Tweedie, D., Li, Y., Greig, N.H., Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders. Br J Pharmacol 166 (2012), 1586–1599.
57. Shaw, K.E., Bondi, C.O., Light, S.H., Massimino, L.A., McAloon, R.L., Monaco, C.M., et al. Donepezil is ineffective in promoting motor and cognitive benefits after controlled cortical impact injury in male rats. J Neurotrauma 30 (2013), 557–564, 10.1089/neu.2012.2782.
58. Sheth, S.A., Iavarone, A.T., Liebeskind, D.S., Won, S.J., Swanson, R.A., Targeted lipid profiling discovers plasma biomarkers of acute brain injury. PLoS ONE, 10(6), 2015, e0129735, 10.1371/journal.pone.0129735.
59. Siman, R., Toraskar, N., Dang, A., McNeil, E., McGarvey, M., Plaum, J., et al. A panel of neuron-enriched proteins as markers for traumatic brain injury in humans. J Neurotrauma 26 (2009), 1867–1877, 10.1089/neu.2009.0882.
60. Stein, D.G., Geddes, R.I., Sribnick, E.A., Recent developments in clinical trials for the treatment of traumatic brain injury. Handb Clin Neurol 127 (2015), 433–451, 10.1016/B978-0-444-52892-6.00028-3.
61. Stoica, B.A., Faden, A.I., Cell death mechanisms and modulation in traumatic brain injury. Neurotherapeutics 7 (2010), 3–12, 10.1016/j.nurt.2009.10.023.
62. Taverni, J.P., Seliger, G., Lichtman, S.W., Donepezil medicated memory improvement in traumatic brain injury during post-acute rehabilitation. Brain Inj 12 (1998), 77–80.
63. Tashlykov, V., Katz, Y., Gazit, V., Zohar, O., Schreiber, S., Pick, C.G., Apoptotic changes in the cortex and hippocampus following minimal brain trauma in mice. Brain Res 1130 (2007), 197–205.
64. Tashlykov, V., Katz, Y., Volkov, A., Gazit, V., Schreiber, S., Zohar, O., et al. Minimal traumatic brain injury induce apoptotic cell death in mice. J Mol Neurosci 37 (2009), 16–24, 10.1007/s12031-008-9094-2.
65. Tuttolomondo, A., Pecoraro, R., Pinto, A., Studies of selective TNF inhibitors in the treatment of brain injury from stroke and trauma: a review of the evidence to date. Drug Des Dev Ther 8 (2014), 2221–2238, 10.2147/DDDT.S67655.
66. Tweedie, D., Milman, A., Holloway, H.W., Li, Y., Harvey, B.K., Shen, H., et al. Apoptotic and behavioral sequelae of mild brain trauma in mice. J Neurosci Res 85 (2007), 805–815.
67. Tweedie, D., Rachmany, L., Rubovitch, V., Zhang, Y., Becker, K.G., Perez, E., et al. Changes in mouse cognition and hippocampal gene expression observed in a mild physical- and blast-traumatic brain injury. Neurobiol Dis 54 (2013), 1–11, 10.1016/j.nbd.2013.02.006.
68. Tweedie, D., Rachmany, L., Rubovitch, V., Lehrmann, E., Zhang, Y., Becker, K.G., et al. Exendin-4, a glucagon-like peptide-1 receptor agonist prevents mTBI-induced changes in hippocampus gene expression and memory deficits in mice. Exp Neurol 239 (2013), 170–182, 10.1016/j.expneurol.2012.10.001.
69. Tweedie, D., Rachmany, L., Rubovitch, V., Li, Y., Holloway, H.W., Lehrmann, E., et al. Blast traumatic brain injury-induced cognitive deficits are attenuated by preinjury or postinjury treatment with the glucagon-like peptide-1 receptor agonist, exendin-4. Alzheimers Dement, 2015, 10.1016/j.jalz.2015.07.489 (pii: S1552-5260(15)02666-7).
70. Walls, M.K., Race, N., Zheng, L., Vega-Alvarez, S.M., Acosta, G., Park, J., et al. Structural and biochemical abnormalities in the absence of acute deficits in mild primary blast-induced head trauma. J Neurosurg, 2015, 1–12, 10.3171/2015.1.JNS141571.
71. Wang, X., Wang, L., Jiang, R., Yuan, Y., Yu, Q., Li, Y., Exendin-4 antagonizes Aβ1-42-induced suppression of long-term potentiation by regulating intracellular calcium homeostasis in rat hippocampal neurons. Brain Res, 2015, 10.1016/j.brainres.2015.09.015 (pii: S0006-8993(15)00713-1).
72. Whelan, F.J., Walker, M.S., Schultz, S.K., Donepezil in the treatment of cognitive dysfunction associated with traumatic brain injury. Ann Clin Psychiatry 12 (2000), 131–135.
73. Xiong, Y., Zhang, Y., Mahmood, A., Chopp, M., Investigational agents for treatment of traumatic brain injury. Expert Opin Investig Drugs 24 (2015), 743–760, 10.1517/13543784.2015.1021919.
74. Xu, W., Yang, Y., Yuan, G., Zhu, W., Ma, D., Hu, S., Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces Alzheimer disease-associated tau hyperphosphorylation in the hippocampus of rats with type 2 diabetes. J Investig Med 63 (2015), 267–272, 10.1097/JIM.0000000000000129.
75. Yang, L.Y., Chu, Y.H., Tweedie, D., Yu, Q.S., Pick, C.G., Hoffer, B.J., et al. Post-trauma administration of the pifithrin-α oxygen analog improves histological and functional outcomes after experimental traumatic brain injury. Exp Neurol 269 (2015), 56–66.
76. Yu, T.S., Kim, A., Kernie, S.G., Donepezil rescues spatial learning and memory deficits following traumatic brain injury independent of its effects on neurogenesis. PLoS ONE, 10, 2015, e0118793, 10.1371/journal.pone.0118793.
77. Zohar, O., Schreiber, S., Getslev, V., Schwartz, J.P., Mullins, P.G., Pick, C.G., Closed-head minimal traumatic brain injury produces long-term cognitive deficits in mice. Neuroscience 118 (2003), 949–955.